SLRX, NCM

Salarius Pharmaceuticals, Inc. (SLRX)

Price (as of October 15)

0.181USD

Correlations

The correlation describes the statistical relationship between the value of two assets over time. Use this relationship to bet against an asset without shorting it or diversify your portfolio more effectively. Learn how you can use correlations to your advantage.

Lowest within Industry

Symbol Correlation

AMLX

Amylyx Pharmaceuticals, Inc.

-0.15

ANPC

AnPac Bio-Medical Science Co., Ltd.

-0.1

ABCL

AbCellera Biologics Inc.

-0.07

ADTX

Aditxt, Inc.

-0.06

ANTX

AN2 Therapeutics, Inc.

-0.05

APRE

Aprea Therapeutics, Inc.

-0.05

AKRO

Akero Therapeutics, Inc.

-0.04

ADGI

Adagio Therapeutics, Inc.

-0.04

APM

Aptorum Group Limited

-0.04

ADPT

Adaptive Biotechnologies Corporation

-0.04

Show more

Highest within Industry

Symbol Correlation

ANEB

Anebulo Pharmaceuticals, Inc.

0.12

ACLX

Arcellx, Inc.

0.1

ABSI

Absci Corporation

0.07

ADIL

Adial Pharmaceuticals, Inc.

0.05

AMTI

Applied Molecular Transport Inc.

0.04

ALLR

Allarity Therapeutics, Inc.

0.04

AKTX

Akari Therapeutics, Plc

0.04

ACIU

AC Immune SA

0.04

ABOS

Acumen Pharmaceuticals, Inc.

0.04

AMAM

Ambrx Biopharma Inc.

0.04

Show more

Profile

Sector:
Healthcare
Industry:
Biotechnology

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.